Renaud Capdeville is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, Renaud Capdeville has authored 52 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 24 papers in Genetics and 16 papers in Rheumatology. Recurrent topics in Renaud Capdeville's work include Chronic Myeloid Leukemia Treatments (29 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Eosinophilic Disorders and Syndromes (16 papers). Renaud Capdeville is often cited by papers focused on Chronic Myeloid Leukemia Treatments (29 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Eosinophilic Disorders and Syndromes (16 papers). Renaud Capdeville collaborates with scholars based in Switzerland, United States and France. Renaud Capdeville's co-authors include Brian Druker, Charles L. Sawyers, Moshe Talpaz, Debra Resta, J. Ford, Elisabeth Buchdunger, Hagop M. Kantarjian, Bin Peng, Nicholas Lydon and Sayuri Ohno-Jones and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Renaud Capdeville
51 papers
receiving
12.5k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
20013.8k citationsBrian Druker, Moshe Talpaz et al.New England Journal of Medicineprofile →
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
20012.1k citationsBrian Druker, Charles L. Sawyers et al.New England Journal of Medicineprofile →
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
20011.5k citationsSandra Silberman, Renaud Capdeville et al.New England Journal of Medicineprofile →
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
20021.5k citationsCharles L. Sawyers, Debra Resta et al.New England Journal of Medicineprofile →
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
20021.1k citationsRenaud Capdeville, Elisabeth Buchdunger et al.Nature Reviews Drug Discoveryprofile →
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
1998724 citationsCorinne Haïoun, Nicolas Ketterer et al.Bloodprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Renaud Capdeville
Since
Specialization
Citations
This map shows the geographic impact of Renaud Capdeville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renaud Capdeville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renaud Capdeville more than expected).
Fields of papers citing papers by Renaud Capdeville
This network shows the impact of papers produced by Renaud Capdeville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renaud Capdeville. The network helps show where Renaud Capdeville may publish in the future.
Co-authorship network of co-authors of Renaud Capdeville
This figure shows the co-authorship network connecting the top 25 collaborators of Renaud Capdeville.
A scholar is included among the top collaborators of Renaud Capdeville based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Renaud Capdeville. Renaud Capdeville is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Capdeville, Renaud, Elisabeth Buchdunger, Juerg Zimmermann, & Alex Matter. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery. 1(7). 493–502.1067 indexed citations breakdown →
10.
Kantarjian, Hagop M., Susan O’Brien, Jörge E. Cortes, et al.. (2002). Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.. PubMed. 8(7). 2167–76.85 indexed citations
11.
Zubay, Geoffrey, Brian Druker, Moshe Talpaz, et al.. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome. 14(13). 733–738.9 indexed citations
Druker, Brian, Moshe Talpaz, Debra Resta, et al.. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine. 344(14). 1031–1037.3811 indexed citations breakdown →
14.
Druker, Brian, Charles L. Sawyers, Renaud Capdeville, et al.. (2001). Chronic Myelogenous Leukemia. Hematology. 2001(1). 87–112.58 indexed citations
15.
Druker, Brian, Charles L. Sawyers, Hagop M. Kantarjian, et al.. (2001). Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. New England Journal of Medicine. 344(14). 1038–1042.2070 indexed citations breakdown →
16.
Zuylen, Lia van, Alex Sparreboom, I. Sklenar, et al.. (2000). The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study. UCL Discovery (University College London).
Haïoun, Corinne, Nicolas Ketterer, Andreas Engert, et al.. (1998). Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.. Blood. 92(6). 1927–32.724 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.